1. Home
  2. AFMD vs CING Comparison

AFMD vs CING Comparison

Compare AFMD & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AFMD
  • CING
  • Stock Information
  • Founded
  • AFMD 2000
  • CING 2012
  • Country
  • AFMD Germany
  • CING United States
  • Employees
  • AFMD N/A
  • CING N/A
  • Industry
  • AFMD Biotechnology: Pharmaceutical Preparations
  • CING Biotechnology: Pharmaceutical Preparations
  • Sector
  • AFMD Health Care
  • CING Health Care
  • Exchange
  • AFMD Nasdaq
  • CING Nasdaq
  • Market Cap
  • AFMD 14.5M
  • CING 13.1M
  • IPO Year
  • AFMD 2014
  • CING 2021
  • Fundamental
  • Price
  • AFMD $0.72
  • CING $4.25
  • Analyst Decision
  • AFMD Strong Buy
  • CING Strong Buy
  • Analyst Count
  • AFMD 5
  • CING 3
  • Target Price
  • AFMD $13.50
  • CING $16.00
  • AVG Volume (30 Days)
  • AFMD 86.2K
  • CING 77.5K
  • Earning Date
  • AFMD 04-08-2025
  • CING 05-07-2025
  • Dividend Yield
  • AFMD N/A
  • CING N/A
  • EPS Growth
  • AFMD N/A
  • CING N/A
  • EPS
  • AFMD N/A
  • CING N/A
  • Revenue
  • AFMD $6,287,085.00
  • CING N/A
  • Revenue This Year
  • AFMD N/A
  • CING $82.10
  • Revenue Next Year
  • AFMD $225.65
  • CING N/A
  • P/E Ratio
  • AFMD N/A
  • CING N/A
  • Revenue Growth
  • AFMD N/A
  • CING N/A
  • 52 Week Low
  • AFMD $0.70
  • CING $1.80
  • 52 Week High
  • AFMD $8.95
  • CING $20.83
  • Technical
  • Relative Strength Index (RSI)
  • AFMD 30.95
  • CING 56.21
  • Support Level
  • AFMD $0.85
  • CING $3.95
  • Resistance Level
  • AFMD $0.89
  • CING $4.44
  • Average True Range (ATR)
  • AFMD 0.05
  • CING 0.27
  • MACD
  • AFMD -0.01
  • CING 0.08
  • Stochastic Oscillator
  • AFMD 22.75
  • CING 76.75

About AFMD Affimed N.V.

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: